In this systematic review and meta-analysis, more intensive compared with less itensive LDL-C lowering was associated with a greater reduction in risk of total and cardiovascular mortality in trials of patients with higher baseline LDL-C levels.
SGLT-2 inhibitors and GLP-1 agonists associated with better mortality outcomes than DPP-4 inhibitors for T2D
SGLT-2 or GLP-1 agonists were associated with lower mortality than DPP-4 inhibitors, placebo, or no treatment.
U.S. transplants using organs from overdose-death donors (ODDs) has increased 24-fold from 2000 to 2016, and transplant outcomes from organs donated by ODDs have been noninferior to those donated by trauma-death donors (TDDs) and medical-death donors (MDDs).
Advanced heart failure patients randomized to receive centrifugal-flow pumps demonstrated higher rates of 2-year survival free of disabling stroke or reoperation to remove or replace their device compared to patients randomized to receive axial-flow pumps.
Veterans receiving pre-end stage renal disease (ESRD) nephrology care in under the Medicare system were more likely to undergo dialysis and had a higher two-year mortality rate than veterans that received pre-ESRD care through the Department of Veteran's Affairs (VA).
In a modern cohort of patients with readily available primary percutaneous coronary intervention, woman experienced greater mortality rates then men following ST-elevation myocardial infarction.
In preterm infants followed over a 3.75-year study period, the overall prevalence of cerebral palsy (CP) decreased from 16% to 12%, the prevalence of severe CP decreased from 26% to 16%, but the prevalence of mild CP increased from 39% to 43%.
Inhibiting mitochondrial responses after intra-articular fracture slows progression of posttraumatic osteoarthritis
Intra-articular fractures (IAFs) often lead to posttraumatic osteoarthritis (PTOA) through mechanisms that involve mitochondria.
BEACON CRC Safety Lead-in Study suggests safety and efficacy of triplet combo Tx metastatic colorectal CA
BEACON CRC is a multicenter, randomized, phase 3 clinical trial evaluating the triplet combination of binimetinib (BINI, a MEK inhibitor) + encorafenib (ENCO, a BRAF inhibitor) + cetuximab (CETUX, an EGFR antibody) for the treatment of metastatic colorectal cancer.
Emergency department (ED) revisit rates among pediatric patients were shown to be underestimated by almost 20% when only revisits that occurred at the same hospital as the original visit were considered.